机译:仅通过三重阴性乳腺癌(亮度)的标准Neoadjuvant化疗单独添加PARP抑制剂Veliparib和Carboplatin(亮度):随机,第3阶段试验
German Breast Grp D-63263 Neu Isenburg Germany;
Baylor Univ Med Ctr Waco TX 76798 USA;
HELIOS Klinikum Berlin Buch Berlin Germany;
Women &
Infants Hosp Rhode Isl Providence RI 02908 USA;
Univ Calif San Francisco Hellen Diller Family Comprehens Canc Ctr San Francisco CA 94143 USA;
AbbVie Inc N Chicago IL USA;
Ulm Univ Ulm Germany;
Brigham &
Womens Hosp 75 Francis St Boston MA 02115 USA;
German Breast Grp D-63263 Neu Isenburg Germany;
AbbVie Inc N Chicago IL USA;
AbbVie Inc N Chicago IL USA;
Natl Surg Adjuvant Breast &
Bowel Project Fdn Pittsburgh PA USA;
US Oncol Texas Oncol Dallas TX USA;
Alicante Univ Gen Hosp ISABIAL GEICAM Spanish Breast Canc Res Grp Alicante Spain;
Harvard Med Sch Dana Farber Canc Inst Boston MA USA;
Natl Surg Adjuvant Breast &
Bowel Project Fdn Pittsburgh PA USA;
Univ Texas MD Anderson Canc Ctr Houston TX 77030 USA;
AbbVie Inc N Chicago IL USA;
Natl Surg Adjuvant Breast &
Bowel Project Fdn Pittsburgh PA USA;
机译:仅通过三重阴性乳腺癌(亮度)的标准Neoadjuvant化疗单独添加PARP抑制剂Veliparib和Carboplatin(亮度):随机,第3阶段试验
机译:添加Carboplatin-Gemcitabine作为二线Neoadjuvant化疗,非响应局部晚期乳腺癌患者标准Neoadjuvant化疗和影响反应的因素评估:随机对照试验
机译:三阴性和HER2阳性早期乳腺癌患者的新辅助卡铂(GeparSixto; GBG 66):一项随机的2期临床试验
机译:可变形图像配准作为改善乳腺癌新辅助化疗后生存预测的工具:ACRIN 6657 / I-SPY-1试验的结果
机译:通过在Neoadjuvant化疗期间使用互动性应用的乳腺癌患者的支持性护理:随机对照试验
机译:添加Carboplatin-Gemcitabine作为二线Neoadjuvant化疗非响应局部晚期乳腺癌患者标准Neoadjuvant化疗和影响反应的因素评估:随机对照试验
机译:每周Nab-κBlitaxel和卡铂治疗的II期试验,用或没有曲妥珠单抗作为非蒽霉素Neoadjuvant化疗,用于局部晚期乳腺癌